Loblaw Makes Deal to Buy Renewable Energy in Alberta
By Stephen Nakrosis
Loblaw will power its drugstores, offices and distribution centers in the province of Alberta with energy generated entirely by wind, sun and water, the company said Thursday.
Loblaw said the agreement with TC Energy is the first of its kind in Canada.
The deal will see TC Energy provide carbon-free energy to 280 locations, including Real Canadian Superstore, as well as the company's offices and distribution centers. The program will eliminate carbon emissions associated with Loblaw's electricity purchases in Alberta and cuts its nationwide enterprise operating emissions by 17%, the company said.
Loblaw said it has committed to net-zero Scope 1 and 2 greenhouse gas emissions by 2040, and net-zero Scope 3 GHG emissions by 2050, as well as to reducing plastic and food waste.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 04, 2023 13:27 ET (17:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure